3rd Party Ad. Not an offer or recommendation by Stocktwits. See disclosure here or
3rd Party Ad. Not an offer or recommendation by Stocktwits. See disclosure here or
Advertisement
3rd Party Ad. Not an offer or recommendation by Stocktwits. See disclosure here or
IOBT IO Biotech Inc
385
$1.24
$0.01
(0.80%)
| Watchers | 385 |
| 52-Wk Low | $0.8163 |
| 52-Wk High | $2.22 |
| Market Cap | $82.35M |
| Volume | 20,859.00 |
| 52-Wk High | $2.22 |
| 52-Wk Low | $0.8163 |
IO Biotech appoints Faical Miyara as CBOThe Fly • 2 months ago
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
Share to Feed
NEW YORK, April 05, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win...
IO Biotech, Inc. (NASDAQ:IOBT - Get Free Report) was the target of a large growth in short interest during the month of March. As of March 15th, there was short interest totalling 81,600 shares, a...
Evotec (OTCMKTS:EVTCY Get Free Report) and IO Biotech (NASDAQ:IOBT Get Free Report) are both medical companies, but which is the better stock? We will compare the two businesses based...
Acciones al alza
SCWorx (NASDAQ:WORX) crecieron un 49,12% para establecerse en los 2,55 d lares durante la sesi n del after-market del mi rcoles.
IO Biotech (NASDAQ:IOBT) experimentaron un repunte...
New nonclinical data strengthen evidence of individual contribution of IO102 and IO103 in controlling tumor growth NEW YORK, March 06, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a...
Completed enrollment of pivotal Phase 3 trial of lead investigational therapeutic cancer vaccine, IO102-IO103, in combination with KEYTRUDA (pembrolizumab), in patients with advanced melanoma...
NEW YORK, Feb. 26, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win...
IO Biotech, Inc. (NASDAQ:IOBT Get Free Report) was the target of a significant drop in short interest during the month of January. As of January 31st, there was short interest totalling...
IO Biotech: A Phase 3 Company Getting No Respect...